NovaBridge Biosciences (NBP) Financial Analysis & Valuation | Quarter Chart
NovaBridge Biosciences (NBP)
NBPPrice: $2.65
Fair Value: 🔒
🔒score
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 ... more
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for ... more
Description
Shares
| Market Cap | $305.46M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Wei Fu |
| IPO Date | 2020-01-17 | CAGR | — |
| Employees | 32 | Website | www.i-mabbiopharma.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
NBP chart loading...
Fundamentals
Technicals
| Enterprise Value | $-42.62M | P/E Ratio | -5.52 |
| Forward P/E | -2.22 | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 0.01 |
| P/CF Ratio | 0.01 | P/FCF Ratio | 0.01 |
| EPS | $-0.48 | EPS Growth 1Y | -89.41% |
| EPS Growth 3Y | -98.22% | EPS Growth 5Y | -96.97% |
| Revenue Growth 1Y | -100% | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -0.11% | ROA | -0.09% |
| ROCE | -0.13% | Current Ratio | 14.47 |
| Quick Ratio | 14.47 | Cash Ratio | 14.17 |
| Debt/Equity | 0.01 | Interest Coverage | — |
| Altman Z Score | 3.17 | Piotroski Score | 2 |